CoChat

Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis

Dawwas, Ghadeer K, Brown, Joshua, Dietrich, Eric, Park, Haesuk · 2019 · The Lancet Haematology

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Background Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being increasingly used in routine clinical practice because of their fixed dosing and favourable pharmacological profiles. Differences in the risk of recurrent venous thromboembolism and major bleeding events between the two drugs are currently unknown. We aimed to compare the effectiveness and safety of apixaban and rivaroxaban in prevention of recurrent venous thromboembolism and major bleeding events in patients with venous thromboembolism. Methods We did a retrospective cohort analysis of data from the Truven Health MarketScan commercial and Medicare Supplement claims databases in the USA. We analysed data for adult patients with newly diagnosed venous thromboembolism (deep vein thrombosis or pulmonary embolism) who were new users of apixaban or rivaroxaban between Jan 1, 2014, and Dec 31, 2016. Patients who did not initiate the study drugs within 30 days of their diagnosis, those without 12 months of continuous enrolment in medical and pharmacy benefits, and those who used other anticoagulants during the baseline period were excluded. The primary effectiveness outcome was the incidence of recurrent venous thromboembolism and the primary safety outcome was the incidence of major bleeding events. Cox-proportional hazard models after propensity score matching were used to calculate the hazard ratio (HR) and 95% CI. Findings After propensity score matching, 15 254 patients were included in the…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2352-3026(18)30191-1

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

See all 84

Metadata

Authors
Dawwas, G. K., Brown, J., Dietrich, E., & Park, H.
Affiliations
University of Florida (US)
Corresponding author
Park, Haesuk
Venue
The Lancet Haematology
Publisher
Elsevier BV
Published
2019-01
Volume
6
Issue
1
Pages
e20-e28
ISSN
2352-3026 (ISSN-L)
OpenAlex
W2905543904
Cited by
84
References
27
Citations by year
2026: 4 · 2025: 5 · 2024: 4 · 2023: 10 · 2022: 12 · 2021: 13 · 2020: 18 · 2019: 17
FWCI
11.60
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Haematology (publishedVersion)
  • PubMed (publishedVersion)
Funders
American Association of University Women
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
apixaban, rivaroxaban, venous thromboembolism, recurrent venous thromboembolism, major bleeding, direct oral anticoagulants, deep vein thrombosis, pulmonary embolism, propensity score matching
MeSH terms
Rivaroxaban, Anticoagulants, Female, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Retrospective Studies, Cohort Studies, Venous Thromboembolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. https://app.cochat.ai/papers/10.1016/s2352-3026(18)30191-1
The paper
Dawwas, G. K., Brown, J., Dietrich, E., & Park, H. (2019). Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(18)30191-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.